青少年肥胖时代的药物体重管理
本文聚焦儿童肥胖的药物治疗进展,重点介绍美国已批准用于儿童减重及超说明书使用但安全范围较宽的药物,旨在为临床医生提供用药指导,并鼓励未来探索青少年肥胖的成功药物治疗及其他干预措施。
要点
- 生活方式干预对中重度青少年肥胖的持续减重效果有限,需考虑药物治疗。
- 本文综述美国当前可用的儿童减重获批药物及超说明书但安全范围较宽的药物。
- 重点涵盖常见及罕见单基因型儿童肥胖的药物治疗进展。
核心结论
- 本综述旨在为临床医生提供儿童青少年肥胖药物治疗的指导,并鼓励未来探索成功的药物治疗及其他干预措施。
研究设计与样本
- 本文为综述,聚焦儿童肥胖药物治疗的最新进展,重点介绍美国已批准用于儿童减重及超说明书使用但安全范围较宽的药物。
主要发现
- 生活方式干预(饮食调整和增加体力活动)对中重度青少年肥胖的持续减重仅观察到有限效果。
- 对重度肥胖儿童和青少年,在考虑减重手术等侵入性操作前,需要包括药物治疗在内的额外循证干预。
临床怎么用
- 原文未据此给出具体用药推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pediatric obesity is a serious health problem in the United States. While lifestyle modification therapy with dietary changes and increased physical activity are integral for the prevention and treatment of mild to moderate obesity in youth, only a modest effect on sustained weight reduction is observed in children and young adults with severe obesity. This underscores the need for additional evidence-based interventions for children and adolescents with severe obesity, including pharmacotherapy, before considering invasive procedures such as bariatric surgery. EVIDENCE ACQUISITION: This publication focuses on recent advances in pharmacotherapy of obesity with an emphasis on medications approved for common and rarer monogenic forms of pediatric obesity. EVIDENCE SYNTHESIS: We review medications currently available in the United States, both those approved for weight reduction in children and "off-label" medications that have a broad safety margin. CONCLUSION: It is intended that this review will provide guidance for practicing clinicians and will encourage future exploration for successful pharmacotherapy and other interventions for obesity in youth.
引用
- Raman V, Gupta A, Ashraf AP, et al. Pharmacologic Weight Management in the Era of Adolescent Obesity. J Clin Endocrinol Metab. 2022. PMID: 35932277. doi:10.1210/clinem/dgac418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。